Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Faron Pharmaceuticals, Webcast, Q4'25

By Inderes3/4/2026, 2:00 PM
Faron Pharmaceuticals

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Juho Jalkanen
00:01 - 00:16

Hello, everyone. Welcome to the Faron Pharmaceuticals annual results webcast for 2025. My name is Juho Jalkanen, the CEO of the company, here with me today is our new CFO, Jurriaan.

Jurriaan Dekkers
00:20 - 01:00

Hi, sir. My name is Julian Dekkers. I started as CFO on the 1st of December 2025, replacing Yrjö, who decided to retire by the end of March this year. I have been working in different global, regional and local finance roles over the last 25 years, with a focus on healthcare and biotech. My last role was at ProQR Therapeutics. CFO of a Dutch-based Nasdaq-listed company. Before that, I've been working at AstraZeneca as CFO in the Netherlands, but also for Acerta Pharma and DaVita Medical Group. Together with my wife, I have two daughters and I enjoy sailing a lot.

Juho Jalkanen
01:01 - 08:38

Thank you. Jurriaan. All right everybody, great to be here with you today. I think we have some fabulous results to go over for the past year. We will be making forward-looking statements also into the future. So our basic disclaimer. And on today's agenda, I'll be taking you first on the main events of the year. Julian will cover the financial results and then delve into the outlook and Q&A. First of all, 2025 has been a remarkable year for us, putting us in a leading position in the treatment of Higher-Risk Myelodysplastic Syndromes. We have delivered outstanding clinical results in both frontline and last line populations, with deep and durable complete remissions and transfusion independence. This translates to significant, long lasting patient benefit. Actually, looking back at our data set, we have been treating a very severely ill population with a high risk score, even highlighting these results further. Meanwhile, unfortunately, some of our competitors in this space have failed, making us now a leading candidate for this indication. In the second half of this year, we had a successful End-of-Phase 2 meeting with the FDA, setting us moving into a Phase 2/3 trial in the Frontline setting. Ultimately, what the FDA wants us to answer is Bex, plus Aza against Aza and placebo in a blinded manner. The ultimate test for a drug for approval with our differentiated biology. And despite the setbacks in the field with our differentiated development plan, which we will go through in more detail, we believe we are positioned for success. We have been doing this all with a solid cash position, even repaying our IPF debt facility in a challenging equity market for biotechs. So truly a strong year of performance in some challenging times. And talking about flying the airplane, we have been building the airplane while we fly it, strengthening both our board and management team. So as you mentioned, we want to thank our longtime CFO, a true Faronian, Mr. Wichmann, who actually will be here with us today handling the Q&A and welcoming you in his position. Then we've strengthened the management board and our PD team with Ralph Hughes, former Pfizer, Mundipharma and PharmaVentures. And to our board, an absolutely marvellous chap, Colin Bond, a big heavyweight, so truly a great team taking the company further. But let's then go in more detail on the events, especially the clinical and regulatory events of the year. So we started the year in January by completing the enrollment of the BEXMAB Phase I/II open-label trial, then received Orphan Designation from EMA and FDA. Fast track had already been given the previous year after completing enrollment. Some three months later, you start seeing the responses. Top-line data was reported in April and then presented back-to-back in oral sessions at ASCO and EHA. First of all, the last-line response rate was 63% and overall survival was 13.4 months. Frontline response rate 72 and CR rate at 28. We actually hit exactly our mark because at this stage, our closest competitor, Venetoclax, a Bcl2 inhibitor, had 75% ORR and 29% CR before moving into their Phase 3 trial. But what we actually saw over the year is that already at EHA, there was more happening in the new frontline population; our Overall Response Rate (ORR) increased initially, and later our Complete Remission (CR) kept on increasing. We saw the responses deepen. We saw the bone marrow become healthy. It started producing more blood cells. So what we actually witnessed over the year was a truly disease modifying drug with Bex. And at the end of the year, our CR landed at 45. Pretty exceptional, and the duration of CR being over 12 months and counting. And the majority of patients also became transfusion independent, which is a very important factor in this indication. Meanwhile, as mentioned, unfortunately Venetoclax failed in their Phase III effort due to multiple reasons. We have taken these learnings and are now mitigating the risks going forward. So this is comparing our data to what has been trialed or what could one expect from AZA. So, the upper part shows our CR rate at 45% again, with good duration, unlike the previous failures. Magrolimab, Venetoclax, Sabatolimab. They were at this point with their Phase 1 or Phase 1/2 trials, seeing CRs from 28 to 33%, and they went mainly directly into a Phase 3 trial after that, where we are not now taking that approach. Then on the lower part, I also want to highlight our last-line survival, which truly stands out. And usually, if you can make it a last-line, you can make it anywhere. So as mentioned, other drugs in development moved directly with this level of margin compared to AZA into their frontline trials against Single-agent AZA. Have a look at our margin. We're still not making that step thanks to the recent learnings. So instead, what we're going for is a Phase IIb in blue here of 90 patients. We are still going to do two doses by the request of the FDA. Even going one dose lower to one mg per kilo, our chosen dose already being three mg per kilo. So that's what we're aiming for. And that is a significant de-risking step for the entire program. And ultimately a very important step also to answer the question of what is the contribution of each agent in this combination treatment. So that could possibly address FDA's question. And we could open the dialogue also for the relapsed/refractory population, for whom there is currently nothing available, so they can access this treatment combination. Then to the financial results. And over to you, Julian.

Jurriaan Dekkers
08:39 - 10:17

We are still not taking that particular step, guided by our recent learnings. We ended the year with a cash position of 12.3 million, which is slightly higher than the 9.5 million at the end of 2024. This is mainly driven by the successful raise of 12 million in February 2025 through a private placement, but also the combination of the convertible bond arrangement for up to 35 million in April 25th. The first tranche of that convertible bond was drawn in April 2025, and partly used to repay the EIB loan. The second tranche was drawn in December 2025 for the amount of €10 million. We ended the year with a loss of 27.3 million and net assets of -18.5. At the end of the year, we had 114.4 million shares outstanding. A couple of highlights I want to share about 2026. In January and February 2026, the company approved the subscriptions based on the special rights in connection with the amortization of the first and second tranche bonds. In February, we announced the plan for the Rights Offering of approximately 40 million to strengthen our capital structure and drive our lead assets. Back to key milestones. In addition, the company may conduct a directed share issue early this week. On the 2nd of March, the AGM authorized the board to resolve on the issuance of a maximum of 80 million new shares. Yesterday, March 3rd, the company had 119.5 million shares outstanding.

Juho Jalkanen
10:19 - 13:48

We ended the year with a loss of 27.3 million and net assets of -18.5 million. So building on our hard work and success in 2025, what do we plan to do next? As Julian already alluded to, we plan to go for more. We plan to raise 40 million to deliver that Phase IIb gold-standard randomized trial showing Bex plus Aza against Aza alone. Further, physicians in the field of MDS, especially relapsed refractory MDS, feel that it is clear that the benefit in last line comes from Bex. They want to produce more data in this setting. So, led by City of Hope, there will be a trial also producing more data for regulatory purposes. In the last line setting. With these excellent results we have been seeing, there is a lot of interest among physicians to investigate Bex further in a number of indications. So we have what we call Investigator-Initiated Trials (IITs), meaning a physician wants to test the drug in the patients they see. This is a very cost-efficient way to generate good data. And we're looking at indications from soft tissue sarcoma to breast cancer, melanoma, lung cancer and AML. We will come back later this spring to give you more details on these upcoming trials. Just to mention, a lot of these are all in regulatory submission. Looking to get first patient in still the first half of this year. So, a strong set of deliverables. So this is the anticipated news flow. And it is a company of our size and resources. Producing this wave of data, I say, is amazing. But this is what we're going for because, as often mentioned in the past, we believe Bex is not only a drug for MDS, but it is a drug to overcome treatment resistance where macrophages are the problem of cancer spread and metastasis. So a very busy schedule ahead for us and our team. Just to wrap up the concluding slide highlighting the essentials. This is what I call the fact sheet. Higher-Risk Myelodysplastic Syndromes, a severe and often deadly hematologic malignancy, remains a profound unmet need. Nothing really out there. Now we seem to be in a leading position. So a very busy schedule ahead for us and our team. We have shown some of the best results so far in this indication. We have shown the best efficacy among drugs in development for this indication in one of the worst populations reported. And now we have what we believe is the best possible development plan to mitigate all known and possibly even unknown risks. So what we're offering is a considerable value inflection, with not a crazy amount of money to deliver the Phase II in. Frontline Higher-Risk MDS, as well as a number of new indications, to prove that Bex works. Further, physicians in the field of MDS, especially relapsed/refractory MDS, feel that it is clear that the benefit in last-line treatment comes from Bex. Over to Q&A then.

Unknown 1
13:59 - 14:14

Okay. There have been a number of questions coming in, and the first one goes to Jurriaan. What is the timetable of the offering planned?

Jurriaan Dekkers
14:14 - 14:20

Yes, I can share that. We are progressing well and we will announce more in due course.

Unknown 1
14:22 - 14:38

The next one comes to you. What trial does the City of Hope want to run? Why does the City of Hope want to run an r/r MDS trial? Trial. Have you considered running one yourself, despite what the FDA stated? The FDA has said.

Juho Jalkanen
14:40 - 16:21

There are multiple reasons for still running a trial in the last-line setting. Ultimately, I feel the most important thing is that there's nothing really out there. So, a trial as such offers a possibility for last-line patients to receive Bex, plus Aza, hopefully gaining benefit at that point. So that is for me and I think for the physicians, one of the most important things: when discussing with the physicians, especially at ASH, they see that it is very clear that the benefit in last line comes from Bex. We actually did discuss with the investigators who are putting together the trial that would they consider having a control arm of Investigator's Choice, which actually would increase the meaning or the power from a regulatory perspective of this data set. They actually felt that that's even unethical, considering that Bex and Aza is available. So they didn't even consider it ethical giving investigator's choice or best supportive care in comparison. And ultimately, actually, it's not about Aza, so they're planning to run it with oral HMAs. What? The physicians in the US are saying that oral HMAS are getting more and more ground. They are likely to become the new standard of care instead of Azacitidine. So for us as a company looking to become the new standard of care agent with HMAs, it is also very important to generate data with these oral new HMAs.

Unknown 1
16:22 - 16:45

And then we have an analyst question. As you observe responses deepening over time in the Phase I/II data that you see. Shall we expect that the CR rates for the randomized phase two portion will be mature enough at year end 27? Or shall we expect more during the follow up period?

Juho Jalkanen
16:46 - 17:03

We are looking into that closely. We believe the readout is positioned where we will have the vast majority. Everybody should be at their CR at the time of the readout, because again, it's going to be a very important readout. So let's not take it too early.

Unknown 1
17:06 - 17:26

And then the following question also regarding your updated BEXMAB data shows strong signals in frontline HR MDS, including Tp53 mutated patients. What's your biomarker-driven strategy for enrichment or companion diagnostic development?

Juho Jalkanen
17:26 - 19:22

In MDS, everybody is CLEVER-1 positive. So there really doesn't seem to be a need for patient selection. So we're not running a diagnostic with it. But there are very interesting subpopulations as mentioned in the question. For example, the Tp53 mutated, where we had an astonishing CR of 70%. And that's an interesting population where really nothing works. Then there's another very interesting subpopulation, which is what the area calls or the field calls low blast count patients, meaning that there's not a lot of those blasts or cancer cells to be killed. We actually seem to work very well in this population, which is seen as a very difficult population because cancer-killing drugs don't really benefit in this population. But we as a disease modifying agent really seem to work in this difficult population. So this is why this is actually important. The Phase 2 part of the Phase 2/3 study is very important for us to then investigate. Doing the final Phase 3 in a specific subpopulation, be it for example, the low blast count population or the TP53 population, because actually then you could get an even more cost-efficient, smaller Phase 3 subpopulation and get approval with a very limited Phase 3, because ultimately you want your first approval. We have already shown that this is still an all-comer drug, but seems to work very well in these subpopulations. So go for a first approval. Go for it quick. It will be used in this entire population.

Unknown 1
19:24 - 19:42

You report that Bexmarilimab. Bexmarilimab Azacitidine combination is very well tolerated in a frail population. What are the most frequent adverse events observed to date? Their grades and any emerging risk signals with longer follow up?

Juho Jalkanen
19:42 - 20:56

Excellent question. Now, with substantially longer follow-up, we're not seeing anything more in the safety signals. So it has remained constant. So nothing new. Even with prolonged treatment, the adverse events remain consistent with what was already observed in this population. The most frequent adverse event is neutropenia, including severe neutropenia. It comes with the disease, and it usually makes it worse. But to provide some clarity and understanding on it. What we're seeing actually with Bex plus Aza, that severe grade 3 to 4 neutropenia is around 34%. And even with single agent Aza, it's been around 60%. So, it looks like the Bex + Aza combination is improving the safety profile of Aza, and this will then possibly be proven in the randomized dataset planned next. And if that is true, that's going to be truly amazing. But there is a biological rationale for this because we are inducing hematopoiesis in these patients and making neutropenia and anemia better.

Unknown 1
20:58 - 21:16

Okay, a couple of more questions. Beyond the planned rights issue. What. And this goes to Jurriaan. Beyond the planned rights issue, what contingencies are in place, e.g. bridge debt, cost deferrals, business development milestones to secure a cash runway of over 12 months.

Jurriaan Dekkers
21:17 - 21:38

Based on the current status of the process. We are comfortable we can extend our cash runway by more than 12 months until the readout of the Phase Two, but the company continuously evaluates all available resources for funding to be able to act in case needed, but more information will be given in due course.

Unknown 1
21:40 - 21:56

Regarding your question, you've decided to run the Phase II portion separately before finalizing Phase III in frontline Higher-Risk Myelodysplastic Syndromes (HR MDS). What are the exact decision gates and success criteria that would trigger a Phase III?

Juho Jalkanen
21:57 - 23:03

Excellent question. So as seen with previous agents, let's say Azacitidine alone would be 17% CR, an increase of 10% to that. So to 27-28% is seen as positive. And this is what led the others to move into a Phase 3, but those were open-label datasets. This was compared to historical comparison. We will now have a randomized dataset in real time. So that is the comfort level of moving into Phase Three and announcing positive results. What is it? Let's take the 17% CR to 27%. But ultimately what we're going to go for. Doubling the CR because then the phase two dataset would have sufficient power. Have some very interesting and meaningful regulatory discussions. So we're looking to. Double it. So let's give an example of how we're actually powering it is that Aza would be. 17 and we would be 35 in CR.

Unknown 1
23:05 - 23:16

And the final question to conclude this 2025 Q&A is an outlook for 2026. What catalysts should investors track during 2026?

Juho Jalkanen
23:17 - 24:02

During 2026, especially, we expect to get first patients in the solid tumor trials, and of course, our planned Rights Offering. That is one big major event coming very soon. Then, we also get the first patient in for Phase II in Higher-Risk MDS. And then towards the end of the year, these IITs are going to be open label again. Can't really say yet when data will come or will be reported, but they will be open label. So they will be reporting data more regularly while we wait for the readout of the actual frontline randomized MDS trial.

Unknown 1
24:04 - 24:06

So that was all from the Q&A.

Juho Jalkanen
24:08 - 24:10

Thank you everyone. Have a great day.

Jurriaan Dekkers
24:10 - 24:11

Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…